Hepatitis B Pipeline Drugs Therapeutics Review H1 2017 provides a snapshot of the global therapeutic landscape of Hepatitis B Drugs (Infectious Disease). The pipeline guide reviews key companies involved in Hepatitis B (Infectious Disease) therapeutics and enlists all their major and minor projects.Report Helps in Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Hepatitis B pipeline 2017 Pharmaceutical and Healthcare guide provides a snapshot of the global therapeutic landscape of Hepatitis B (Infectious Disease) including reviews pipeline therapeutics for Hepatitis B (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. Report reviews key companies involved in Hepatitis B (Infectious Disease) therapeutics and enlist all their major and minor projects.
Complete report Hepatitis B Pipeline Review 2017 spread across 353 pages available at: www.reportsnreports.com/reports/10…view-h1-2017.html.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis B (Infectious Disease).
This Report helps you to find and recognize significant and varied types of therapeutics under development for Hepatitis B (Infectious Disease) and - Formulate corrective measures for pipeline projects by understanding Hepatitis B (Infectious Disease) pipeline depth and focus of Indication therapeutics.
Market Scope of Report:
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
Hepatitis B (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 8, 27, 26, 4, 56, 35 and 4 respectively.
Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 3, 9 and 5 molecules, respectively.
Get report at www.reportsnreports.com/reports/10…view-h1-2017.html.
Key Companies Discussed in Report: Abivax SA, AiCuris GmbH & Co KG, AIMM Therapeutics BV, Akshaya Bio Inc, Alnylam Pharmaceuticals Inc, Altimmune Inc, Altravax Inc, Amarna Therapeutics BV, Arbutus Biopharma Corp, Arcturus Therapeutics Inc, Arrowhead Pharmaceuticals Inc, Assembly Biosciences Inc, Beijing Kawin Technology Share-Holding Co Ltd, Beijing Minhai Biotechnology Co Ltd, Benitec Biopharma Ltd, Biological E Ltd, BioStar Pharmaceuticals Inc, Bolder Biotechnology Inc, BrightGene Bio-Medical Technology Co Ltd, Bukwang Pharm Co Ltd, CaroGen Corp, Celltrion Inc, Chong Kun Dang Pharmaceutical Corp, Chromis Therapeutics Inc, Cocrystal Pharma Inc, ContraVir Pharmaceuticals Inc, CyTuVax BV, Dicerna Pharmaceuticals Inc, Dong-A Socio Holdings Co Ltd, Dynavax Technologies Corp, Ensemble Therapeutics Corp, Enyo Pharma SA, eTheRNA Immunotherapies NV, F. Hoffmann-La Roche Ltd, GeneCure LLC, GeoVax Labs Inc, Gilead Sciences Inc, GlaxoSmithKline Plc, Green Cross Corp, Hanmi Pharmaceuticals Co Ltd, Humabs BioMed SA, Huons Co Ltd, Ildong Pharmaceutical Co Ltd, Immunotope Inc, Indian Immunologicals Ltd, Intellia Therapeutics Inc, Ionis Pharmaceuticals Inc, ISA Pharmaceuticals BV, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Johnson & Johnson, Kineta Inc, Leukocare AG, LG Chem, Ltd., Ligand Pharmaceuticals Inc, Medivir AB, Mucosis BV, MultiCell Technologies Inc, Oncolys BioPharma Inc, Panacea Biotec Ltd, Pfenex Inc, PharmaEssentia Corp, Profarma, Profectus BioSciences Inc, Replicor Inc, Rodos BioTarget GmbH, Samjin Pharmaceutical Co Ltd, Sanofi, Sanofi Pasteur SA, Scynexis Inc, Shantha Biotechnics Ltd, Sinovac Biotech Ltd, Spring Bank Pharmaceuticals Inc, TCM Biotech International Corp, Theravectys SA, THEVAX Genetics Vaccine USA Inc, Tomegavax Inc, Transgene SA, Vaxine Pty Ltd, VBI Vaccines Inc, Vical Inc, ViroStatics srl, patitis B - Pipeline by VLP Biotech Inc, Zydus Cadila Healthcare Ltd.
Access Licensed Copy of report at www.reportsnreports.com/purchase.aspx?name=1020023
Hepatitis B Drug Profiles Discussed: cyproheptadine hydrochloride + prazosin hydrochloride, disulfiram + selegiline, 18-MC, A-705253, ABT-436, ADX-71441, amitifadine, arbaclofen placarbil, AT-1001, AT-200, baclofen , CERC-501, CTDP-002, Drugs to Target HAT and HDAC for Hepatitis B and Anxiety Disorders, GET-73, gabapentin enacarbil ER, ibudilast , JDTic , nalmefene , naltrexone hydrochloride , naltrexone hydrochloride SR, odelepran hydrochloride, OMS-527, ondansetron hydrochloride, PF-05190457, SKL-10406.
The pipeline guide reviews key companies involved in Hepatitis B (Infectious Disease) therapeutics and enlists their entire major and minor projects. The pipeline guide evaluates Hepatitis B (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
Reasons to Access:
Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under development for Hepatitis B (Infectious Disease). Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. Formulate corrective measures for pipeline projects by understanding Hepatitis B (Infectious Disease) pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Table of Contents: